ecancer

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

8 Mar 2021

Cabozantinib most effective treatment for metastatic papillary kidney cancer

Dr Sumanta Pal - City of Hope, Duarte, USA

26 Feb 2021

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma

Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA

26 Feb 2021

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma

Dr Sia Daneshmand - University of Southern California, Los Angeles, USA

24 Feb 2021

Challenges in nursing GU cancer patients during COVID-19

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK

24 Feb 2021

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK

17 Feb 2021

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

15 Feb 2021

ASCO GU 2021: Renal cancer roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

15 Feb 2021

OncoAlert and ecancer weekly roundup for February 07 - 13, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

15 Feb 2021

OncoAlert and ecancer weekly roundup for February 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

9 Feb 2021

Emergence of PARP inhibitors in prostate cancer

Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, London, UK

5 Feb 2021

Advances and treatment strategies for metastatic hormone-sensitive prostate cancer

Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, London, UK

5 Feb 2021

More from ecancer